A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects

J Pharmacol Exp Ther. 2015 Mar;352(3):590-601. doi: 10.1124/jpet.114.220392. Epub 2015 Jan 12.

Abstract

Orexins (OXs) are peptides produced by perifornical (PeF) and lateral hypothalamic neurons that exert a prominent role in arousal-related processes, including stress. A critical role for the orexin-1 receptor (OX1R) in complex emotional behavior is emerging, such as overactivation of the OX1R pathway being associated with panic or anxiety states. Here we characterize a brain-penetrant, selective, and high-affinity OX1R antagonist, compound 56 [N-({3-[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-yl}methyl)-5-(trifluoromethyl)pyrimidin-2-amine]. Ex vivo receptor binding studies demonstrated that, after subcutaneous administration, compound 56 crossed the blood-brain barrier and occupied OX1Rs in the rat brain at lower doses than standard OX1R antagonists GSK-1059865 [5-bromo-N-({1-[(3-fluoro-2-methoxyphenyl)carbonyl]-5-methylpiperidin-2-yl}methyl)pyridin-2-amine], SB-334867 [1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea], and SB-408124 [1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea]. Although compound 56 did not alter spontaneous sleep in rats and in wild-type mice, its administration in orexin-2 receptor knockout mice selectively promoted rapid eye movement sleep, demonstrating target engagement and specific OX1R blockade. In a rat model of psychological stress induced by cage exchange, the OX1R antagonist prevented the prolongation of sleep onset without affecting sleep duration. In a rat model of panic vulnerability (involving disinhibition of the PeF OX region) to threatening internal state changes (i.e., intravenous sodium lactate infusion), compound 56 attenuated sodium lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity. In conclusion, OX1R antagonism represents a novel therapeutic strategy for the treatment of various psychiatric disorders associated with stress or hyperarousal states.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / metabolism
  • Aminopyridines / pharmacology
  • Aminopyridines / therapeutic use*
  • Animals
  • Arousal / drug effects
  • Arousal / physiology*
  • CHO Cells
  • Cricetinae
  • Cricetulus
  • HEK293 Cells
  • Humans
  • Hypnotics and Sedatives
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Orexin Receptor Antagonists*
  • Orexin Receptors / metabolism*
  • Piperidines / metabolism
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Protein Binding / physiology
  • Rats
  • Rats, Sprague-Dawley
  • Stress, Psychological / metabolism*
  • Stress, Psychological / prevention & control*

Substances

  • 5-bromo-N-(1-(3-fluoro-2-methoxybenzoyl)-5-methylpiperidin-2-yl)methylpyridin-2-amine
  • Aminopyridines
  • Hypnotics and Sedatives
  • Orexin Receptor Antagonists
  • Orexin Receptors
  • Piperidines